Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The U.S. Transthyretin Amyloidosis Treatment Market, by Drug (Tafamidis, Diflunisal, Patisiran, Inotersen, and Others), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed), and Wild Type), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) is expected to be valued at US$ 36.9 million in 2018 and is estimated to exhibit a CAGR of 52.4% over the forecast period (2018–2026).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1919
Absence of alternative treatment options, expected drug launches in 2018, and rapid acceptance of the newly available therapies are the factors that are expected to drive the U.S. transthyretin amyloidosis treatment market growth over the forecast period. For instance, in 2017, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation (BTD) to Patisiran, which is indicated for the treatment of hereditary ATTR (hATTR) amyloidosis with polyneuropathy. Moreover, in November 2017, Alnylam Pharmaceuticals, Inc. initiated a new drug application (NDA) for Patisiran and the company announced to receive the U.S. FDA approval of its NDA and priority review status for Patisiran, in February 2018.
Additionally, major players are actively focusing on developing new therapies for the treatment transthyretin amyloidosis, as there is no treatment available in the U.S. for transthyretin amyloidosis, which is further expected to create lucrative growth opportunities for manufacturers in the U.S. transthyretin amyloidosis market over the forecast period.
In January 2018, the new drug application (NDA) of Inotersen was accepted for priority review by the U.S. Food and Drug Administration and July 2018 was set for Prescription Drug User Fee Act (PDUFA), which was later postponed to October 6, 2018. Inotersen launch is expected to further boost the transthyretin amyloidosis treatment market growth.
Browse 22 Market Data Tables and 25 Figures spread through 116 Pages and in-depth TOC on U.S. Transthyretin Amyloidosis Treatment Market, by Drug (Tafamidis, Diflunisal, Patisiran, Inotersen, and Others), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed), and Wild Type), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Forecast to 2026
To know the latest trends and insights prevalent in the U.S. Transthyretin Amyloidosis Treatment Market Press Release, click the link below: https://bit.ly/2FSbVyU
Additionally, key players in the market are focusing on collaborations, acquisitions, and partnerships, in order to expand their product offerings. For instance, AKCEA-TTR-LRX, a Ligand Conjugated Antisense (LICA), developed by Akcea Therapeutics (affiliate of Ionis Pharmaceuticals), was expected to enter clinical trials in 2018 for the treatment of all forms of ATTR amyloidosis.
Moreover, in March 2018, Ionis Pharmaceuticals completed a previously announced transaction with its affiliate Akcea Therapeutics that was related to commercialization rights of Inotersen and AKCEA-TTR-LRX globally (given to Akcea Therapeutics). Alnylam Pharmaceuticals, Inc. developed the drug in collaboration with Sanofi and the deal related to Patisiran was restructured inJanuary 2018. Under the new deal, Alnylam regained rights for global development and commercialization of its investigational RNAi therapeutics such as Patisiran and ALN-TTRsc02, whereas Sanofi assumed full responsibility for the development and commercialization of Fitusiran (Hemophilia A and B).
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1919
Key Takeaways of the U.S. Transthyretin Amyloidosis Treatment Market:
- The U.S. transthyretin amyloidosis treatment market is expected to exhibit a CAGR of 52.4% over the forecast period (2018-2026), attributed to product launches by manufacturers such as Alnylam Pharmaceuticals, Inc., and Ionis Therapeutics
- Patisiran (Alnylam Pharmaceuticals, Inc.) is currently ahead of its competitors in terms of approval and subsequent commercialization, and Alnylam may benefit from the first-mover advantage
- Therapies in the pipeline belong to the class of gene therapies (RNAi therapeutics and antisense drugs), which have the potential to cure the underlying cause of the disease
- Key players operating in the U.S. transthyretin amyloidosis treatment market include Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.
Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1919
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027